Y
Yukari Okubo
Researcher at Tokyo Medical University
Publications - 121
Citations - 1709
Yukari Okubo is an academic researcher from Tokyo Medical University. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 19, co-authored 97 publications receiving 1083 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Shinichi Imafuku,Masaru Honma,Yukari Okubo,Mayumi Komine,Mamitaro Ohtsuki,Akimichi Morita,Noriko Seko,Naoko Kawashima,Saori Ito,Tomohiro Shima,Hidemi Nakagawa +10 more
TL;DR: The data from this study shows that secukinumab can become one of the potent treatment options for GPP and the area of erythema with pustules improved as early as week 1 and resolved by week 16 in most of the patients.
Journal ArticleDOI
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich,Kim A. Papp,Andrew Blauvelt,Richard G. Langley,April W. Armstrong,Richard B. Warren,Kenneth B. Gordon,Joseph F. Merola,Yukari Okubo,Cynthia Madden,Maggie Wang,Christopher Cioffi,Veerle Vanvoorden,Mark Lebwohl +13 more
TL;DR: Bimekizumab was more efficacious than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis and the bimekzumab safety profile was consistent with that observed in previous studies.
Journal ArticleDOI
Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council.
Bruce Strober,Caitriona Ryan,Peter C.M. van de Kerkhof,Joelle M. van der Walt,Alexa B. Kimball,Jonathan Barker,Andrew Blauvelt,Marc Bourcier,Andre V. E. de Carvalho,Arnon D. Cohen,Peter Foley,Colby C. Evans,Paolo Gisondi,Christopher E.M. Griffiths,Mahira Hamdy El-Sayed,Cristina Eschevarria,Andrew Yule Finlay,Robert E. Kalb,Craig L. Leonardi,Chuck Lynde,Ruth Murphy,Masamoto Murakami,Yukari Okubo,Errol P. Prens,Lluís Puig,Marieke M B Seyger,Lone Skov,Tadashi Terui,Fernando Valenzuela,Nicole L. Ward,Jashin J. Wu,Min Zheng +31 more
TL;DR: A consensus statement is developed that describes two categories of psoriasis severity, while accounting for special circumstances where patients may require systemic therapy.
Journal ArticleDOI
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
TL;DR: Targeting IL-23 and its associated immune cascade with guselkumab may be a safe and useful therapeutic option for treatment of PPP.
Journal ArticleDOI
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Tadashi Terui,Satomi Kobayashi,Yukari Okubo,Masamoto Murakami,Richuan Zheng,Hitomi Morishima,Ryosuke Goto,Takayuki Kimura +7 more
TL;DR: Efficacy end points improved consistently through week 52, and health-related quality of life also improved significantly, meaning Guselkumab may be an effective and safe treatment option for management of palmoplantar pustulosis.